Janssen Pharmaceutica Nv

Sanofi-aventis

Sanofi-synthelabo

Valore

Bruno Schoentjes

Alain Philippe Poncelet

Sophie Philippe Coupa

Christophe Meyer

Luc Van Hijfte

Lieven Meerpoel

Pierre-Henri Storck

Virginie Sophie Poncelet

Jean Fernand Armand Lacrampe

Bruno Giethlen

Viviane Van Dorsselaer

Camille Georges Wermuth

Frans E Janssens

Joannes Theodorus Maria Linders

Julien Georges Pierre-Olivier Doyon

Jean Wagnon

Daniel Frehel

Claudine Serradeil-Le Gal

Janine Arts

Werner Constant Johan Embrechts

Georges Garcia

Didier Jean-Claude Berthelot

Marc Willems

Richard Roux

Gaston Stanislas Marcella Diels

Marcel Viellevoye

Bernard Tonnerre

François Maria Sommen

Jean-Marie Contreras

Muriel Joubert

Luc August Laurentius Ver Donck

Imre Christian Francis Csoka

Yvan René Ferdinand Simonnet

Sylvie Baltzer

Matthias Luc Versele

Gaston Stanislas Diels

Imre Christian Csoka

Berthold Wroblowski

Alain Di Malta

Carina Leys

Philipp Ermert

Pierre Despeyroux

Delphine Yvonne Raymonde Lardeau

Bronislav H May

Paul J Niebes

Yannick Aimé Eddy Ligny

Julien Estager

Jean Fernand Lacrampe

Sophie Coupa

Sophie Descamps

Matthias Luc Aime Versele

Nathalie Claudie Isabelle Amblard

Pierre Despey-Roux

Saïd Rachidi

Jean Ferand Armand Lacrampe

Yannick Aimè Eddy Ligny

Arnaud Marcel Pierre Piettre

Frans Eduard Jenssens

Matthias Luc Aimé Versele

Arnaud Marcel Piettre

Francois Maria Sommen

Werner Constant Embrechts

Yannick Aime Ligny

Bronislav Henric May

The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, m, p, s, t, R, R, R, R, R, R, R, R, X, Y, Q and Z have defined meanings.

Inhibitors of the interaction between MDM2 and P53

The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Macrocylic pyrimidine derivatives

The invention relates to a gastroenteric therapeutic composition for oral administration, comprising a compound of monomeric (+)-catechin and at least one basic amino acid, said composition being characterized in that it is used in the form of a complex of (+)-catechin and at least one basic amino acid or at least one derivative or precursor of a basic amino acid for the curative and/or preventive treatment of cancer, said complex having a molar equivalence ratio of the monomeric (+)-catechin to the at least one basic amino acid or the at least one basic amino acid derivative of between 1:1 and 1:2.5.

Composition comprising a complex of (+)-catechin and amino acid for the treatment and prevention of cancer

The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.

Benzocycloheptane and benzoxepine derivatives

The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I). 

Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53

The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof;  The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.

This invention concerns substituted diaza-spiro-[4.4]-nonane derivatives having neurokinin antagonistic activity, in particular NK1 antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment and/or prophylaxis of schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, pain, in particular visceral and neuropathic pain, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease (COPD) and micturition disorders such as urinary incontinence. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in claim. 

[object Object]

The present invention provides compounds of formula (I), their use for the treatment of cancer as well as pharmaceutical compositions comprising said compounds of formula (I). 

Indole derivatives as anticancer agents

The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R, R, R, R, R, R, R, X, Y, Q and Z have defined meanings.

The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, t, R, R, R, R, R, R, R, Q, Y and Z have defined meanings.

Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and P53

The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, s, t, R, R, R, R, R, X, Y, Q, Z, G, E and D have defined meanings.

Inhibitors of the interaction between MDM2 and p53

The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof;provided that the compound is other than or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.

The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R, R, A and Z have defined meanings.

This invention concerns substituted oxa-diaza-spiro-[5.5]-undecanone derivatives having neurokinin antagonistic activity, in particular an NKantagonistic activity, an NKantagonistic activity, a combined NK/NKantagonistic activity and a combined NK/NK/NKantagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment and/or prophylaxis of schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, pain, in particular visceral and neuropathic pain, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease (COPD) and micturition disorders such as urinary incontinence. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim. 

Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists

Growing community of inventors

Bois-Guillaume, France

Bruno Schoentjes